Cannabis Investments

FDA Fast-Tracks New Cancer Drug for Skin Cancer While Cannabis Science Offers Topical Treatment for Basal Cell Carcinoma with No Apparent Side Effects

February 1, 2012

Cannabis Science, Inc. (OTCBB:CBIS.OB) a pioneering U.S. biotech company developing pharmaceutical cannabis (marijuana) products, is very pleased to inform that news of recent FDA Cancer Drug Approval puts Cannabis Science in a very good position moving forward with its current Cancer solutions.

Erivedge was given a fast six-month review because there are no approved treatments for advanced basal cell carcinoma. See FDA Announcement here.

“For the FDA to approve a drug with serious side effects within six months, suggests that the Cannabis Science should receive similar consideration when we submit our application for the treatment of basal cell carcinoma,” said Dr. Melamede, CEO, Cannabis Science. Click here for further information on side effects associated with Erivedge.

Cannabis Science is currently assisting numerous cancer patients suffering from a variety of cancers, who are self-medicating with cannabis extracts. Cannabis Science extracts can be legally used in humans in states allowing medical marijuana. This situation puts Cannabis Science in the unique position of knowing the effectiveness of its formulations before applying to the FDA. The success of Cannabis Science approach is dramatically demonstrated with the photo documentation available on our website www.cannabisscience.com under breaking news. Similar positive results from treating various cancer types have been observed following systemic treatments when more than a topical treatment is required.

“Whereas treatment with Erivedge is estimated to cost $7,000 per month for a total treatment plan of approximately $75,000, the Cannabis Science treatment is estimated to cost at least ten fold less,” added Dr. Melamede. “Because of the FDA focus on protecting the public from the possible harm that is so often associated with conventional pharmaceuticals, the reality of what is happening in medical marijuana states needs be incorporated into the federal approval process. Americans suffering from various forms of cancer, including skin cancer, need the FDA to place patients first when considering our up coming application.”

A comparison between Erivedge and Cannabis Science treatments is informative. According to the FDA: “The most common side effects observed in patients treated with Erivedge were muscle spasms, hair loss, weight loss, nausea, diarrhea, fatigue, distorted sense of taste, decreased appetite, constipation, vomiting, and loss of taste function in the tongue.” Cannabis-based botanicals actually can be used to treat most of these side effects.

Dr. Melamede adds, “How ironic it is that the medicine of the past will become the medicine of the future as safe and cost effective cannabis-based botanicals displace conventional pharmaceuticals for the benefit of mankind.”

You can view the above images as well as all Cannabis Science’ success on the Cannabis Science website www.cannabisscience.com, click “Breaking News” and you will find the associated news releases and images from of each patient. You can view each patient’s documentation and images by clicking: “View Images of 1st Self-Medicated Patient & The Apparent Success”, “View Images of 2nd Self-Medicated Patient & The Apparent Success”, and “View Images of 3rd Self-Medicated Patient & His Apparent Success.”

About Cannabis Science, Inc.
Cannabis Science, Inc. is at the forefront of pharmaceutical grade medical marijuana research and development. The second formulations will address the needs of patients choosing to use concentrated cannabis extracts to treat their ailments. Eventually, all Americans will have access to a safe and effective FDA approved medicine regardless of which state they live in. To maintain that marijuana is a dangerous, addictive drug with no medical value is scientifically absurd. Cannabis medicines, with no effective lethal dose, are far safer than aspirin, acetaminophen, and most other OTC drugs that kill thousands of Americans every year.

The Company works with world authorities on phytocannabinoid science targeting critical illnesses, and adheres to scientific methodologies to develop, produce and commercialize phytocannabinoid-based pharmaceutical products. In sum, we are dedicated to the creation of cannabis-based medicines, both with and without psychoactive properties, to treat disease and the symptoms of disease, as well as for general health maintenance.

Forward Looking Statements
This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing works such as “anticipate,” “seek,” intend,” “believe,” “plan,” “estimate,” “expect,” “project,” “plan,” or similar phrases may be deemed “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company’s reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc. does not undertake any duty nor does it intend to update the results of these forward-looking statements.

Contacts
Cannabis Science Inc.
Dr. Robert J. Melamede, 1-888-889-0888
President & CEO
info@cannabisscience.com
www.cannabisscience.com
or
Robert Kane, 1-561-234-6929
Investor Relations Management
rkane@cannabisscience.com
info@cannabisscience.com
www.cannabisscience.com

View full post on News Releases

Cancer Patient Success Prompts Cannabis Science To Begin FDA Investigational New Drug (IND) Application Process

January 25, 2012

DENVER–(BUSINESS WIRE)– Cannabis Science, Inc. (OTCBB: CBIS.OB) a pioneering U.S. biotech company developing pharmaceutical cannabis (marijuana) products, is pleased to inform that the current progress and success with their numerous self-medicated cancer patients, has lead the Company to immediately begin the Investigational New Drug (IND) application process that will target cancer treatment.

Cannabis Science is currently tracking numerous cancer patients, who are self-medicating with cannabis extracts. The Company has evident success with these patients, which creates support to submit an IND application to the FDA. The prescription pharmaceutical market is the number one target market for Cannabis Science, and with having the appropriate backup for the application process, it is all very promising for the Company and cancer patients worldwide.

Cannabis Science currently has documented images for the first three apparently successful self-medicated cancer patients, and the Company is waiting for more documentation and images associated with other patients. The first patient had basal cell carcinoma (skin cancer) on her face, and after applying the topical cannabis extracts within 10 days it appeared the lesion was gone. Cannabis Science received documentation from her surgeon that she would not need to undergo any surgical procedures and was free of cancer cells. The second patient, who has basal cell carcinoma on their arm, has gotten dramatic results. Their treatment has been completed, and Cannabis Science is just waiting for a full biopsy report from the patient’s physician to inform that they are free of cancer cells. A special case, involves a third patient with severe squamous cell carcinoma on his head. His physician prior to using cannabis extracts had told this patient, that there was nothing more that could be done. Cannabis Science has gotten drastic results, along with photographed documentation of the treatment process. This patient’s treatment is still in progress, but with photographic evidence you can see the effectiveness of the cannabis-based extracts.

You can view the photos and information of these patients on the Cannabis Science website www.cannabisscience.com, click the button “Breaking News” and you will find the associated news releases of each patient. You can also view each different patient’s documentation and images by clicking the buttons, “View Images of 1st Self-Medicated Patient & The Apparent Success”, “View Images of 2nd Self-Medicated Patient & The Apparent Success”, and “View Images of 3rd Self-Medicated Patient & His Apparent Success”.

Cannabis Science is in an excellent position to begin the FDA process for prescription cancer medications. Cannabis Science is seeing even more success with other self-medicated cancer patients, and will get updated reports on them as well. All of the positive outcomes from the patients create a suitable foundation to enter the FDA market of prescription drugs.

About Cannabis Science, Inc.
Cannabis Science, Inc. is at the forefront of pharmaceutical grade medical marijuana research and development. The second formulations will address the needs of patients choosing to use concentrated cannabis extracts to treat their ailments. Eventually, all Americans will have access to a safe and effective FDA approved medicine regardless of which state they live in. To maintain that marijuana is a dangerous, addictive drug with no medical value is scientifically absurd. Cannabis medicines, with no effective lethal dose, are far safer than aspirin, acetaminophen, and most other OTC drugs that kill thousands of Americans every year.

The Company works with world authorities on phytocannabinoid science targeting critical illnesses, and adheres to scientific methodologies to develop, produce and commercialize phytocannabinoid-based pharmaceutical products. In sum, we are dedicated to the creation of cannabis-based medicines, both with and without psychoactive properties, to treat disease and the symptoms of disease, as well as for general health maintenance.

Forward Looking Statements
This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing works such as “anticipate,” “seek,” intend,” “believe,” “plan,” “estimate,” “expect,” “project,” “plan,” or similar phrases may be deemed “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company’s reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc. does not undertake any duty nor does it intend to update the results of these forward-looking statements.

Contact:
Cannabis Science Inc.
Dr. Robert J. Melamede, 1-888-889-0888
President & CEO
info@cannabisscience.com
www.cannabisscience.com
or
Robert Kane, 1-561-234-6929
Investor Relations Management
rkane@cannabisscience.com
info@cannabisscience.com
www.cannabisscience.com

View full post on News Releases

There is no denying the fact that the predicament of our modern impasse lies with the tussling against the unlawful drug trafficking and the spread of drug infatuation. Nowadays this impenetrability is awfully discriminating and as such it is explicitly associated with the success of the brawling against crime, or malfunction if we inadequately fight the observable fact, which is the burning question of the day and in reality a whole multiplicity of social and economic issues. And of course it is most strongly knotted with the number one theme in the world – the struggle against terrorism. Narco-business is one of the financial sources for terrorist groups and bandit gangs. It is well known that 80 percent of heroin is supplied to the world market from some sources involving in terrorism and social immoral activities. And gunmen of certain movements control drug transfer from there to Central Asia and on to Europe through Russia. Terrorism and drugs are absolutely kindred phenomena. They have common roots and similar destructive power. Terrorism, just as narco-business, has a ramified international network and without doubt bears a transnational character. Narco-business also has a pronounced economic aspect. For this reasons, drug addiction as a medical and social phenomenon doesn’t exist without a criminal narco-market network as well as drug sales.

In recent survey it has been detected many countries have today become a colossal user of the narco-potion. Today, according to official data alone, there are about 269,000 drug addicts and there exists more than the actual figure for drug users is much higher. Moreover, the narco-market structure is changing. The drug producers have a conspicuous growth of the share of exceedingly strenuous drugs, and in the first place Afghan heroin, the proportion of which in total drug use constitutes 28 percent out. In the hypercritical state of Modern world, there grows local drug production in the country, including that of synthetic drugs, cheap and producing instant dependence. What’s particularly dangerous is that the number of such laboratories by some expert estimates has greatly increased in Russia in recent years. Unfortunately, the social base of drug addiction is expanding. Today this ailment has percolated to all sections of society, encompassing the territory – world wide, especially the depressed areas. This is leading to an avalanche-like spread of AIDS. By experts’ estimates as revealed so far in the world statistics, 90 percent of the HIV-infected catch the virus precisely through intravenous drug use. As before, most of the drug addicts – up to 53 percent – are persons with no definite occupation. It is they who strengthen the army of distributors now as well, which in its turn gives go up to a crime flare.

The despondent strain is that drug addiction has got much younger. The total number of sick persons has increased by nine times over the recent period, and among adolescents by 17 times. The “average age” of those who have for the first time tasted drugs barely exceeds 14 years. In drug trafficking In this context, it is evident from the recent survey, Russia is not only a “terminal,” but also a transshipment point. Drug syndicates have undertaken a real expansion in Russia. It has become a favorable transit passageway for them.

By experts’ estimates, one dollar invested in a narcotic – for example, in Afghanistan – grows into super profits after the sale of the drug item in European countries. And the overall volume of your and our market – the Russian market – exceeds 1 billion dollars. Power agencies obviously put up with the brunt of the fight against the drug mafia. Here we will inevitably have to strengthen, both financially and with cadres, all of the services that are associated with this kind of activity – the fight against the drug mafia. By the detention of drug goods alone we cannot solve this problem. Only a small part of merchandise gets confiscated. Experience shows that the detainees are mostly petty retailers, and sometimes also those who need being treated themselves.

In this connection it is time in general to revise the criteria of work in this direction. We must put up a barrier to all the ways for drug penetration into illegal trade, smash the infrastructure of drug networks and eliminate demand. The reasons for the powerful drug “invasion” lie not only in the proximity of the countries of the Golden Crescent. For it there are loopholes in Russia itself – financial, legal, and administrative and, of course, social. In addition to one more important aspect of the problem – the attitude to this question of society itself. Drugs are percolating even to social institutions which are responsible for the upbringing of young people baptized to serve as an blockage to drug pushers, the enlightening institutions, regrettably, are fetching a bridgehead for drug allocation. We’re encountering the indifference of both the school and parents. Today every fifth recruit brings to the army with him an experience of drug use with all the ensuing consequences for security agencies.

Drug use should not be permissible to become a subculture or fashion. Unfortunately, we’re observing signs of this. Even worse, books are being freely sold that propagate a “narcotic lifestyle.” All of these manifestations of a grave social disease have to be fought by legal and administrative and educational methods. Here a substantial workload falls on legislators, legislation in all-purpose, and law enforcement practice. Changes ought to be directed toward stiffening criminal responsibility for the most dangerous narco-crimes. Thought should also be given to the introduction of a practice of replacing punishment with coercive treatment for drug addicts.

Marijuana and hashish are those drugs produced from the plant Indian hemp and accordingly, visible effects of the drugs including reddening of the eyes caused by distention of blood vessels, and enlargement of the pupils. Effects on the mind vary and in general visual awareness is increased and ideas flow more quickly. These drugs are not addictive and there is no substantiation that they harm the body. There is jeopardy, however, that the drug taker’s sense of judgment will be distorted so that reckless or foolish behavior can result. Lysergic acid DI-ethyl amide (LSD) is an example of a hallucinogenic drug, so called because it gives rise to dramatic eccentricity. The effects of LSD trip are erratic and seem to depend upon the mood of the user without more ado before taking the drug. It could for instance intensify awareness and perception to the point at which the user undergoes mystical experiences or it may intensify a depressed, fearful or agitated mood with horrendous results. One more problem with LSD is that very miniature quantities have powerful effects, and since illegitimately formed drugs vary in quality drug takers can never be sure how much they are taking. An overdose of LSD can result in insanity or death. Another problem with LSD is that very small quantities have powerful effects, and since illegally produced drugs are extracted from the seed capsules of the opium poppy. Opiates are medically important as painkillers. But drug takers use them because they give rise to approach of well beings, pleasure, and power. It may be apologetic to articulate when the effects wear off the taker becomes anxious and depressed and is tempered to take another dose to restore a good mood, a course that can lead to addiction. Morphine, heroine, and other drugs that are often injected involve the risk of infection from dirt hypodermic needles. Besides this, Barbiturates and amphetamines are used immediately to relieve anxiety and as sleeping pills. But they are dangerous because the dosage must be continually increased to be effective. Barbiturates are often used in combination with amphetamines and other stimulants. These reduce the sleepiness induced by barbiturates with a feeling of mental alertness. Amphetamines harm the health by reducing the appetite, by causing sleeplessness, and by reducing the body’s ability to fight infection. Hence it is clear that the drug as have been reflected so far is illegal unless they are used under medical supervision. The illegal use or sale of these drugs can result in colossal punishment under the enactment of the government as implied.

In view of the above it is evident that the possibility of providing castigation for drug advocacy needs to be geared up. The state parties ought not to limit to isolated establishments, every one on behalf of the state need to create a network of healing centers where up-and-coming methods of treatment and return of people to a normal social life should be the prime factor. Regrettably, drug addiction has ceased to be a “disease of the rich only,” and hence we must expand the network of state institutions for the poor. But at the same time we need to develop and create a transparent legal base for the work of private sectors. An important set of tasks is connected with the eradication of financial channels for narco-business, which can be cut off not only by fighting against unlawful elements, but also through the use of a whole system of special measures as a tentative flow.

As a high growth, high profitability of natural medicine, led to the capital market more and more attention, but as the network of natural medicines will not be business as long as the “concern” would be a lot of “money-burning” created the myth of value-added . It is predicted that natural medicine can achieve double-digit market growth, herbal ingredients, herbs and their extracts, and the market is a developing market with great growth potential.

Natural medicine in the Western market turnover is growing. In recent years, consumption in Western markets more to an average of 16% speed increase. The current global natural medicines (including traditional medicines countries) with annual sales of 14.5 billion U.S. dollars, accounting for half of Europe, Germany ranks first in Western Europe, Germany is also the first European plant treatments developed countries. European sales accounted for 78% of the total, per capita consumption reached 14.4 pounds, mainly for ginkgo biloba, ginseng, evening primrose oil, Western Arborvitae Leaf, artichokes, garlic and other products. German pharmaceutical scientists from China, the first extract of Ginkgo biloba standardized extract of Ginkgo biloba “strong ladder Browning” (containing 24% ginkgo flavone, if Lactone 6%), total global sales of extract of Ginkgo biloba are more than two billion U.S. dollars. In addition, the development of hypericin Germany is the world’s first, now ranks first in the world sales. So far, Germany has dozens of herbal list of prescription drugs into the hospital. France’s second-largest market for herbal medicines for the European Union, per capita consumption of 1.56 pounds, the United Kingdom with knowledge about natural medicines, demand for rapid growth, has become one of the world’s leading herbal market.

The impact of natural medicine in Asia is also growing in Japan the past 5 years of herbal prescriptions to 15% annual growth rate of human consumption levels up to 7.3 U.S. dollars. In recent years, ginseng essence, velvet fine, Ganoderma films and so high tonic medicine has been popular in Thailand, the annual consumption of 5,000 million U.S. dollars, South Korea also used to use natural medicine, which originated in South Korean doctors of Chinese medicine in China, Chinese manufacturers are now 80, accounting for 22.2% of the total pharmaceutical companies. Since the Asian financial crisis, Japan and other Southeast Asian countries, demand has dropped, but based on its wide range of applications on the basis of natural medicine, the future market potential.

U.S. natural medicine has not yet obtained the legal status of medicines, all plant treatment agent in the U.S. market only to “food supplements” name sales. According to statistics, the United States selling natural medicine as hypericin, extract of Ginkgo biloba, echinacea, valerian, kava root, evening primrose oil, Maozhuacao grass, Gymnema Sylvestre, snow lotus extract and fish oil preparations above herbal preparations absorbed with fish oil for the U.S. market in recent years the most popular best-selling natural medicines, the sales total of about U.S. natural pharmaceutical preparations 90% of the market.

The world, more and more people trust natural medicine, scientists are hard at work developing new natural medicines. If American researchers (Merck senior technical staff) in the African jungle to find a fungus, “pseudo-black regiment shell”, isolated from a 5-ring compounds were similar to the role of insulin, and can be administered orally. European scientists found that the extract from the snowdrop “Snow amine” can cure Alzheimer’s disease (senile dementia), cannabis extract can cure multiple sclerosis, from the Philippines production of “Eucheuma” (a kind of seaweed, also known as “carrageenin”), a natural polysaccharide extracted “carrageenan” to cure “Duchenne disease” (sexual [FS: PAGE] muscular dystrophy) and so on. Hong Kong SAR Government: Hong Kong the next 10 years, intends to build “Chinese medicine in Hong Kong.” Taiwan plans to spend 8 billion -120 billion Taiwan dollars (300 000 000 -5 100 million U.S. dollars) in a few years to accelerate development of new agents. China’s exports in traditional Chinese medicine preparation the first step towards encouraging. Currently there are Shanghai’s “Xing Ling”, day law of “Danshen Dripping Pill” and some other provinces and cities by the U.S. FDA approved Chinese agents have entered clinical trials, they will put in a few years the U.S. market.

At present, some far-sighted eyes were targeted multinational plant resources has great powers such as Brazil’s tropical rain forests, China, India and Latin America geographical advantage in Latin America, Peru, Nicaragua, Colombia and other countries set a research base for new plant resources . South Africa and the United States on 100 million U.S. dollars investment in South Africa established a new plant resource development agencies. Nigeria has set up a new plant raw material. Japan is also vigorously natural drug research, only Tsumura, “Shun paradise” is equivalent to one year production value of the total exports of traditional Chinese medicine. Some research institutes in China and the United States some big companies, thousands of plant material from China were screened with anti-cancer drugs, anti-virus a new type of plant components. Such as the Pacific yew bark extract from the anticancer drug “Taxol” in order to plant C. acuminata as raw materials, “CPT” series of derivatives has been officially approved by FDA for the anti-cancer drug. Also to natural plant Ginkgo biloba, Valerian, Saw Palmetto, Hypericum perforatum, kava root, white Scopalia japonica maxin, garlic oil, aloe vera, lutein and other health products for the manufacture of raw materials and “green cosmetics” has been one after another . U.S. scientists on the Chinese herbal medicine Scutellaria, Andrographis paniculata, cordyceps and other high interest in the extracts of natural medicines on the market is expected to become the new best-selling varieties.

When humans return to nature, the pursuit of a healthy voice higher, the natural medicine industry into the capital markets triggered a new focus to the world development trend of natural medicine, herbal produce as a big country in drug cultivation, processing, production and so on, development consistent with GMP, GAP and other relevant quality standards, Chinese industrial production and the introduction of advanced production technology, to strengthen the deep processing of Chinese medicine products, increase product added value and gold content, so that our Sinopharm in the international drug market on the natural place.

The industry analysis specialist’s new report, “Neuropathic Pain – Drug Pipeline Analysis and Market Forecasts to 2015″ is an essential source of information and analysis on the global neuropathic pain market. The report identifies the key trends shaping and driving the global neuropathic pain market. The report also provides insight on the prevalent competitive landscape and the emerging players expected to bring significant shift in the market positioning of the existing market leaders. Most importantly, the report provides valuable insight on the pipeline products within the global neuropathic pain sector.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by team of industry experts.

Estimated the global neuropathic pain market to be valued at $4.8 billion in 2008. It is expected to grow at a Compound Annual Growth Rate (CAGR) of approximately 4.3% from $4.8 billion in 2008 to $6.5 billion in 2015. This growth will be supported by the increase in the aging population, increased treatment seeking behavior, increased uptake of the current products. Diagnosis rate remains as one of the barriers for the growth of the market. The available treatment options are moderately successful in meeting the market demand. There is still a need for better therapy and there exists the unmet need. There exists a market potential for any new entrant that will cater these unmet needs. There is enormous opportunity for any drug that would offer better or retain the efficacy provided by the current players with increased safety than the current products.

Analyzed that there are over 111 molecules in various stages of the pipeline. Vimpat, Qutenza, Fentora are some of the pipeline candidates in the regulatory filing stage for approval. The late stage pipeline includes some of the promising molecules like Ralfinamide, NP-1, Sativex. These drugs may retain the similar efficacy and offer better safety and may benefit the patient population who cannot endure the available drugs. The newer therapies may intensify the existing competition and there seems to be a possibility of price war.

Scope of the Report

The scope of the report includes:

Annualized global neuropathic pain market revenues data from 2006 to 2008, forecast forward for 7 years to 2015.

Geographies covered in this report include the US, the UK, Italy, Spain, Germany, France, and Japan.

Pipeline analysis data providing a split across different phases, mechanism of action being developed and emerging trends. Key classes of mechanism of action includes opioid receptor agonists, cannabinoid receptor modulators, NMDA antagonists, protein kinase inhibitors, ion channel targetters, serotonin norepinephrine reuptake inhibitors, adenosine agonists, cytokine modulators, AMPA antagonists, nicotinic receptor agonists, TRPV1 receptor agonists, selective subtype sodium channel antagonists, iNOS/nNOS dual inhibitors.

Analysis of the current and future market competition in the global neuropathic pain market. Key future market players covered are NeurogesX, Cephalon Inc., UCB S.A., Newron Pharmaceuticals, EpiCept Corporation, GW Pharmaceuticals, Johnson & Johnson, Avanir pharmaceuticals, GlaxoSmithKline plc., AstraZeneca.

Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Key topics covered include strategic competitor assessment, market characterization, unmet needs and implications for future market associated with neuropathic pain.

Reasons to Buy

The report will enhance your decision making capability in a more rapid and time sensitive manner. It will allow you to:

Develop and design your in-licensing and out-licensing strategies through review of pipeline products and technologies and by identifying companies with the most robust pipeline.

Develop business strategies by understanding the trends shaping and driving the global neuropathic pain market.

Drive revenues by understanding key trends, innovative products and technologies, market segments and companies likely to impact the global neuropathic pain market in future.

Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

What’s the next big thing in the global neuropathic pain market landscape? – Identify, understand and capitalize.

For more information,please visit:

http://www.aarkstore.com/reports/Neuropathic-Pain-Drug-Pipeline-Analysis-and-Market-Forecasts-to-2015-40530.html